Searched for
US MARKET PHARMACEUTICALS
Indian envoy pitches greater pharma exports, Chinese investment to deepen tiesIndia's ambassador to China, Vikram Doraiswami, stressed the importance of expanding access to Chinese markets for Indian pharmaceutical co...- Markets may consolidate; micro, small and mid-caps could lead alpha generation, says Quant Mutual FundQuant Mutual Fund expects Indian equities to consolidate after the recent rally but believes micro-, small- and mid-cap stocks will drive a...
- US, West Asia drag India's pharma exports growthIndian pharmaceutical exports to the US, its largest market, saw a dip in early fiscal months, alongside a slight decline in shipments to W...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...
- Shantha Biologics to Make Injectable Drug Cartridges for Novo NordiskShantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable...
- Why did market rise today? Sensex gains 444 points, Nifty closes above 24,000. 3 key factorsIndian stock markets surged on Wednesday, breaking a two-day losing spell. Positive global sentiment and other factors propelled investor c...
- Sensex rises over 150 points, Nifty above 23,900 as investors weigh Iran tensions, weak monsoon concernsIndian stock markets opened the second half of 2026 with modest gains after recent declines. Investors are closely watching escalating US-I...
- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- Ahead of Market: 10 things that will decide D-Street action on MondayIndian markets closed marginally higher on Thursday after a volatile expiry session, with the Sensex rising 109 points to 77,100.47 and the...
- For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...
- Alembic Pharma gets USFDA nod for generic influenza treatment drugAlembic Pharmaceuticals has secured USFDA approval for its generic oseltamivir phosphate oral suspension, a key treatment for influenza. Th...
- India, US move closer to interim trade deal after Goyal-Greer talksIndia and the United States have made significant headway in their Bilateral Trade Agreement negotiations, with both nations expressing str...
- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
- India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI AayogIndia's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soonIndian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...
Load More
